MX2009011897A - Formulacion de soluciones de azucar para la ultracentrifugacion continua para la purificacion de virus. - Google Patents

Formulacion de soluciones de azucar para la ultracentrifugacion continua para la purificacion de virus.

Info

Publication number
MX2009011897A
MX2009011897A MX2009011897A MX2009011897A MX2009011897A MX 2009011897 A MX2009011897 A MX 2009011897A MX 2009011897 A MX2009011897 A MX 2009011897A MX 2009011897 A MX2009011897 A MX 2009011897A MX 2009011897 A MX2009011897 A MX 2009011897A
Authority
MX
Mexico
Prior art keywords
virus
formulation
sugar solutions
virus purification
continuous ultracentrifugation
Prior art date
Application number
MX2009011897A
Other languages
English (en)
Inventor
Manfred Reiter
Wolfgang Mundt
Leopold Grillberger
Artur Mitterer
Horst Schafhauser
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011897(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int filed Critical Baxter Int
Publication of MX2009011897A publication Critical patent/MX2009011897A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención proporciona un método para la purificación de un virus o un antígeno de virus que comprende proporcionar una preparación de virus y centrifugar dicha preparación de virus en un gradiente de un azúcar establecido por la adición de dos o más capas de azúcar reguladas en su pH de diferente concentración. El método conduce a rendimientos más altos y reduce la agregación no deseada del virus o antígeno de virus incrementando el volumen de la combinación pico.
MX2009011897A 2007-05-04 2008-04-30 Formulacion de soluciones de azucar para la ultracentrifugacion continua para la purificacion de virus. MX2009011897A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92769207P 2007-05-04 2007-05-04
PCT/EP2008/003531 WO2008135229A2 (en) 2007-05-04 2008-04-30 Formulation of sugar solutions for continuous ultracentrifugation for virus purification

Publications (1)

Publication Number Publication Date
MX2009011897A true MX2009011897A (es) 2010-02-04

Family

ID=39596388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011897A MX2009011897A (es) 2007-05-04 2008-04-30 Formulacion de soluciones de azucar para la ultracentrifugacion continua para la purificacion de virus.

Country Status (18)

Country Link
US (4) US20100239609A1 (es)
EP (1) EP2155864B1 (es)
JP (2) JP5745717B2 (es)
KR (4) KR20100017594A (es)
CN (2) CN104694489A (es)
AR (1) AR066449A1 (es)
AU (1) AU2008248904B2 (es)
BR (1) BRPI0811499B8 (es)
CA (1) CA2687119C (es)
CL (1) CL2008001294A1 (es)
HK (2) HK1138318A1 (es)
IL (1) IL201898A (es)
MX (1) MX2009011897A (es)
PE (1) PE20090284A1 (es)
RU (1) RU2503719C2 (es)
TW (1) TWI472620B (es)
WO (1) WO2008135229A2 (es)
ZA (1) ZA200907743B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811499B8 (pt) * 2007-05-04 2021-05-25 Baxalta GmbH métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
CA2750055A1 (en) * 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
CN102985536B (zh) 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
CN101948813B (zh) * 2010-09-04 2012-07-25 国家海洋局第一海洋研究所 一种刺参球形病毒的分离方法
JP6719468B2 (ja) 2014-12-16 2020-07-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 大規模なウイルス精製方法
EP3255054A1 (en) * 2016-06-06 2017-12-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the purification of biological macromolecular complexes
PT3535388T (pt) 2016-11-04 2023-06-27 Takeda Pharmaceuticals Co Métodos de purificação de vírus adeno-associados
CN110352353B (zh) 2017-03-03 2023-12-15 武田药品工业株式会社 确定腺相关病毒制剂的效价的方法
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法
WO2022229703A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. New aav8 based immune escaping variants
EP4330270A2 (en) 2021-04-30 2024-03-06 Takeda Pharmaceutical Company Limited Aav8 capsid variants with enhanced liver targeting
CA3234817A1 (en) * 2021-10-12 2023-04-20 Remo MOOMIAIE Systems and methods for manufacturing of therapeutic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US4217418A (en) * 1978-05-08 1980-08-12 Merck & Co., Inc. Recovery of small particles by flow centrifugation
EP0005408B1 (en) 1978-05-08 1982-12-01 Merck & Co. Inc. A process for the direct extraction of small size particles of up to 50 nm from a protein aceous liquid
JPH06247995A (ja) * 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル（α２−６）ラクトテトラオシルセラミド
RU2080124C1 (ru) * 1995-10-19 1997-05-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения живой гриппозной вакцины
ES2377968T3 (es) * 2003-04-01 2012-04-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y composiciones farmacéuticas
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1739801A (zh) * 2004-08-27 2006-03-01 上海生物制品研究所 一种流行性感冒病毒裂解疫苗及其制备方法
BRPI0811499B8 (pt) * 2007-05-04 2021-05-25 Baxalta GmbH métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.

Also Published As

Publication number Publication date
KR20100017594A (ko) 2010-02-16
CL2008001294A1 (es) 2009-03-06
KR101998537B1 (ko) 2019-07-09
JP2015061538A (ja) 2015-04-02
US20160060603A1 (en) 2016-03-03
JP5745717B2 (ja) 2015-07-08
KR20170065671A (ko) 2017-06-13
KR20150082676A (ko) 2015-07-15
HK1211320A1 (en) 2016-05-20
AU2008248904A1 (en) 2008-11-13
US9732327B2 (en) 2017-08-15
US8969533B2 (en) 2015-03-03
BRPI0811499B8 (pt) 2021-05-25
AU2008248904B2 (en) 2014-10-09
HK1138318A1 (en) 2010-08-20
RU2503719C2 (ru) 2014-01-10
IL201898A (en) 2013-11-28
CN101688187A (zh) 2010-03-31
US20100239609A1 (en) 2010-09-23
CA2687119A1 (en) 2008-11-13
BRPI0811499A2 (pt) 2014-10-14
TWI472620B (zh) 2015-02-11
US20080274138A1 (en) 2008-11-06
US20170369853A1 (en) 2017-12-28
EP2155864B1 (en) 2013-07-17
PE20090284A1 (es) 2009-03-17
JP6031082B2 (ja) 2016-11-24
TW200914615A (en) 2009-04-01
ZA200907743B (en) 2010-09-29
KR101873891B1 (ko) 2018-07-04
WO2008135229A2 (en) 2008-11-13
IL201898A0 (en) 2011-08-01
JP2010525798A (ja) 2010-07-29
WO2008135229A3 (en) 2008-12-31
RU2009144980A (ru) 2011-06-10
KR101744430B1 (ko) 2017-06-20
AR066449A1 (es) 2009-08-19
EP2155864A2 (en) 2010-02-24
CA2687119C (en) 2021-06-08
BRPI0811499B1 (pt) 2019-06-04
KR20180077305A (ko) 2018-07-06
CN104694489A (zh) 2015-06-10

Similar Documents

Publication Publication Date Title
MX2009011897A (es) Formulacion de soluciones de azucar para la ultracentrifugacion continua para la purificacion de virus.
WO2012145238A3 (en) Methods for reducing an adverse immune response to a foreign antigen in human using cd4-binding molecules
WO2009100331A3 (en) Compositions methods and kits for enhancing immune response to a respiratory condition
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011109365A3 (en) Concentrated protein formulations and uses thereof
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2014028777A3 (en) Methods of treating a tauopathy
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2007079190A3 (en) Device and method for enhancing immune response by electrical stimulation
WO2014089209A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2012140127A3 (en) Method for priming of t cells
EA201001285A1 (ru) Применение 25-oh d3 для воздействия на физиологию мышц человека
WO2009140657A3 (en) Method of treating chronic heart failure
WO2012006500A3 (en) Monoclonal antibodies against hepatitis c virus core protein
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
CL2008001563A1 (es) Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras.
WO2014064609A3 (en) HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASES
WO2010014622A3 (en) In vitro model for modulating the blood brain barrier and methods of screening
WO2014049438A3 (en) Method of non-invasive determination of glucose concentration in blood and device for the implementation thereof
WO2012110968A3 (en) Treatment of fistulizing crohn's disease
EP3153861A3 (en) Biomarkers for predicting response to a cancer vaccine
EP2700318A4 (en) USES, METHODS AND BIOLOGICAL COMPOSITIONS OF THE GENUS PAECILOMYCES FOR THE REGULATION, PREVENTION AND ERADICATION OF PHYTOPARASITES IN SOLANATE CULTURES
WO2011106378A3 (en) Oral b12 therapy
BR112014013723A2 (pt) formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico

Legal Events

Date Code Title Description
FG Grant or registration